A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen. “The likelihood of...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2dJM1xr
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 20 February 2018 Source: Journal of Neuroradiology Author(s): Matthias Barral, Louis Lassalle, Cyril ...
-
Robert Schumann regnes som en av de store romantiske komponistene, særlig anerkjent er hans klaver- og kammermusikk. Han startet på utdanni...
-
Thesis Statement Creator: Directions: This web page explains the different parts to a thesis statement and helps you create your own. You ca...
-
Abstract Therapeutic angiogenesis is an experimental frontier in vascular biology that seeks to deliver angiogenic growth factors to ischem...
-
Oncolytic viruses show specific targeting and killing of tumor cells and therefore provide attractive assets for cancer immunotherapy. In pa...
-
Differential diagnosis of a paroxysmal neurological event: Do neurologists know how to clinically recognize it? Epilepsy Behav. 2017 J...
-
Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is a rare and aggressive subtype of urothelial carcinoma. Its deceptive morph...
-
Publication date: 1 April 2017 Source: Cancer Letters, Volume 390 Author(s): Run Huang, Yang Yu, Xiangyun Zong, Xiaolin Li, Lisi Ma, Qi Zh...
-
Abstract Current industrial fabrication and automation systems are faced with the challenge of obtaining great accuracy and fine manipulat...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου